이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Jianmin Pharmaceutical GroupLtd 관리

관리 기준 확인 2/4

Jianmin Pharmaceutical GroupLtd's CEO는 Jun Wang, Sep2022 에 임명되었습니다 의 임기는 1.75 년입니다. 는 CN¥ 20.11M 가치에 해당하는 회사 주식의 0.23% 직접 소유합니다. 20.11M. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 1.8 년입니다.

주요 정보

Jun Wang

최고 경영자

CN¥891.4k

총 보상

CEO 급여 비율	n/a
CEO 임기	1.8yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	1.8yrs
이사회 평균 재임 기간	1.8yrs

최근 관리 업데이트

Recent updates

We Think Jianmin Pharmaceutical GroupLtd (SHSE:600976) Can Stay On Top Of Its Debt

Jun 30

We Ran A Stock Scan For Earnings Growth And Jianmin Pharmaceutical GroupLtd (SHSE:600976) Passed With Ease

May 21

We Think That There Are Issues Underlying Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Earnings

Apr 26

CEO

Jun Wang (47 yo)

1.8yrs

테뉴어

CN¥891,400

보상

Mr. Jun Wang was Vice President of KPC Pharmaceuticals,Inc until September 08, 2020. He is Managing Director of Jianmin Pharmaceutical Group Co.,Ltd. He is Director and President of Jianmin Pharmaceutical...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jun Wang	President	1.8yrs	CN¥891.40k	0.23% CN¥ 17.6m
Chaoyang Cheng	Financial Director	1.8yrs	CN¥511.20k	0.056% CN¥ 4.3m
Zhenbo Hu	VP & Director	less than a year	CN¥210.40k	데이터 없음
Jie Zhou	Secretary	1.8yrs	CN¥408.80k	0.024% CN¥ 1.9m
Xuejun Pei	Vice President	1.8yrs	CN¥540.00k	0.12% CN¥ 9.3m
Zhijun Huang	Vice President	1.8yrs	CN¥540.00k	0.11% CN¥ 8.2m

1.8yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 관리: 600976 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jun Wang	President	1.8yrs	CN¥891.40k	0.23% CN¥ 17.6m
Zhenbo Hu	VP & Director	less than a year	CN¥210.40k	데이터 없음
Qin He	Chairman	1.8yrs	CN¥2.10m	0.27% CN¥ 20.8m
Qijing Xiao	Chairman of the Supervisory Board	1.8yrs	데이터 없음	데이터 없음
Yunpei Guo	Independent Director	1.8yrs	CN¥90.00k	데이터 없음
Rong Pei	Director	1.8yrs	CN¥60.00k	데이터 없음
Liang Xu	Director	1.8yrs	CN¥60.00k	데이터 없음
Shuqu Li	Independent Director	1.8yrs	CN¥90.00k	데이터 없음
Hu Jian	Supervisor	1.8yrs	데이터 없음	데이터 없음
Li Chen	Supervisor	1.8yrs	데이터 없음	데이터 없음
Jingqiu Tang	Supervisor	1.8yrs	데이터 없음	데이터 없음
Zhi Yang	Independent Director	1.8yrs	CN¥90.00k	데이터 없음

1.8yrs

평균 재임 기간

53.5yo

평균 연령

경험이 풍부한 이사회: 600976 의 이사회는 경험(평균 재직 기간 1.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Jianmin Pharmaceutical GroupLtd 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Jianmin Pharmaceutical Group Co.,Ltd., Annual General Meeting, Apr 08, 2024

No independent directors

Recent updates

We Think Jianmin Pharmaceutical GroupLtd (SHSE:600976) Can Stay On Top Of Its Debt

Jianmin Pharmaceutical Group Co.,Ltd. to Report First Half, 2024 Results on Aug 16, 2024

We Ran A Stock Scan For Earnings Growth And Jianmin Pharmaceutical GroupLtd (SHSE:600976) Passed With Ease

We Think That There Are Issues Underlying Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Earnings

First quarter 2024 earnings released: EPS: CN¥0.65 (vs CN¥0.65 in 1Q 2023)

Jianmin Pharmaceutical Group Co.,Ltd. to Report Q1, 2024 Results on Apr 20, 2024

Jianmin Pharmaceutical Group Co.,Ltd., Annual General Meeting, Apr 08, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorates as stock falls 16%

Jianmin Pharmaceutical Group Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 16, 2024

Jianmin Pharmaceutical Group Co.,Ltd. to Report First Half, 2023 Results on Aug 16, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 16%

No independent directors

Third quarter 2022 earnings released: EPS: CN¥0.84 (vs CN¥0.59 in 3Q 2021)

Investor sentiment improved over the past week

Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) intends to acquire Zhejiang Huafang Medical Care Co., Ltd from Holley Group Company Limited, Zhejiang Holley Investment Management Co., Ltd. and Suzhou Yuanyi Zhiyuan Equity Investment Partnership (Limited Partnership) for CNY 15.2 million.

Second quarter 2022 earnings released: EPS: CN¥0.73 (vs CN¥0.64 in 2Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Now 22% undervalued after recent price drop

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.59 (vs CN¥0.45 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.64 (vs CN¥0.25 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.46 (vs CN¥0.12 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥0.60 in FY 2019)

Jianmin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 16, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day low: CN¥24.68

Third quarter earnings released

Jianmin Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 21, 2020

New 90-day high - CN¥25.64

First half earnings released

Jianmin Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 13, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령